Tuesday - February 10, 2026

Category Archives: Science

Treatment Resistant Hypertension Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Treatment-Resistant Hypertension Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Hypertension pipeline landscape. It covers the Treatment Resistant Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading →

Liver Cirrhosis Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight

DelveInsight’s, “Liver Cirrhosis Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Liver Cirrhosis pipeline landscape. It covers the Liver Cirrhosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Relapsing-Remitting Multiple Sclerosis Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Oncolytic Virus Clinical Trial Pipeline Gains Momentum: 120+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical … Continue reading →

Scleroderma Clinical Trial Pipeline Expands as 40+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Scleroderma Pipeline Insight 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Scleroderma pipeline landscape. It covers the Scleroderma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Scleroderma pipeline therapeutics … Continue reading →

Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in the Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical … Continue reading →

ANCA Vasculitis Pipeline Shows Strong Momentum as 12+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “ANCA Vasculitis Pipeline Insight 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →